Vera Therapeutics To Present Three Posters At The American Society Of Nephrology Kidney Week 2023 Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Vera Therapeutics (NASDAQ:VERA) announced that three abstracts on its product candidate atacicept in immunoglobulin A nephropathy (IgAN) have been selected for poster presentations at the American Society of Nephrology (ASN) Kidney Week 2023. The presentations will include data from the ORIGIN 3 Pivotal Phase 3 study and additional analysis of week 36 data from Phase 2b ORIGIN study. The data supports atacicept's potential as a long-term disease-modifying IgAN therapy.
October 13, 2023 | 2:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vera Therapeutics' announcement of the presentation of three abstracts on atacicept at the ASN Kidney Week 2023 could potentially boost investor confidence in the company's product pipeline.
The presentation of positive data on atacicept at a major conference could potentially increase investor confidence in Vera Therapeutics' product pipeline and its ability to bring effective treatments to market, which could have a positive impact on the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100